15-Lipoxygenase (15-LOX, also called 15-LO or ALOX15) is a non-heme iron-containing dioxygenase enzyme that stereospecifically inserts molecular oxygen at the carbon-15 position of polyunsaturated fatty acids (PUFAs), particularly arachidonic acid, EPA, and DHA. This enzymatic oxygenation initiates the biosynthesis of Specialized pro-resolving mediators (SPMs) including Lipoxins, Resolvins, Protectins, and Maresins, making 15-LOX the master enzyme of resolution of inflammation. In humans, two isoforms exist: 15-LOX-1 (expressed in epithelial cells, eosinophils, and macrophages) and 15-LOX-2 (expressed in skin, prostate, and lung), with 15-LOX-1 being the primary SPM-generating isoform.
Picture It: Think of 15-LOX as the quality control inspector at the end of a construction site. After the demolition crew (neutrophils) and initial builders (pro-inflammatory macrophages) have done their work creating controlled damage and inflammation, the construction site needs to be cleaned up and rebuilt. The 15-LOX inspector walks along the PUFA assembly line β omega-3 and omega-6 fatty acids arriving like raw lumber β and marks them with a red stamp at exactly position 15. This stamp is a molecular oxygen tag that completely changes what these fatty acids can become.
Without this inspector, the raw materials just sit there or get turned into pro-inflammatory products by other enzymes (like 5-LOX making leukotrienes). But with the 15-position stamp, these fatty acids become blueprints for resolution: lipoxins (the "stop fighting" signal), resolvins (the cleanup crew coordinators), protectins (the tissue protectors), and maresins (the repair specialists). The inspector doesn't show up at the beginning of construction β they arrive when it's time to transition from demolition to rebuilding. If the inspector never shows up or is deficient, the construction site becomes an abandoned mess: chronic inflammation, failed resolution, tissue damage that never heals. The quality of the lumber matters too β if you only deliver omega-6 boards (arachidonic acid) instead of omega-3 (EPA/DHA), you get fewer and less effective cleanup blueprints.
15-LOX catalyses the stereospecific dioxygenation of PUFAs through a free radical mechanism involving non-heme iron (FeΒ²βΊ/FeΒ³βΊ) at the active site:
Basic Catalytic Cycle:
- FeΒ²βΊ (resting state) β FeΒ³βΊ (activated by substrate binding)
- Hydrogen abstraction from carbon-13 of PUFA β carbon-centered radical
- Oxygen insertion at carbon-15 β peroxyl radical intermediate
- Electron transfer and protonation β hydroperoxy product (HPETE/HPEPE/HPDHE)
- Product release β FeΒ²βΊ regeneration
Substrate-Specific Pathways:
graph TD
A[15-LOX] --> B[Arachidonic Acid]
A --> C[EPA]
A --> D[DHA]
B --> E[15-HPETE]
E --> F[15-HETE]
E --> G[Lipoxin A4/B4]
C --> H[15-HPEPE]
H --> I[Resolvin E1/E2/E3]
D --> J[17-HpDHA]
J --> K[Protectin D1]
J --> L[Maresin 1/2]
J --> M[Resolvin D1/D2/D3/D4/D5/D6]
N[Aspirin-acetylated COX-2] --> O[15R-HETE]
O --> P[15-epi-Lipoxin A4/B4]
P --> Q[ATL - Aspirin-Triggered Lipoxins]
Transcellular Biosynthesis (Lipoxins):
- Neutrophil 5-LOX converts arachidonic acid β 5-HPETE β LTA4
- LTA4 released and transferred to platelet or epithelial cell
- Recipient cell 15-LOX converts LTA4 β Lipoxins (LXA4, LXB4)
- This requires cell-cell contact or close proximity
- Provides spatial and temporal control of resolution
Aspirin-Modified Pathway:
- Aspirin irreversibly acetylates COX-2 at Serine-530
- Acetylated COX-2 switches from PGE2 synthesis to 15R-HETE production
- 15R-HETE β 15-epi-lipoxins (aspirin-triggered lipoxins, ATLs)
- ATLs are more resistant to metabolic inactivation than native lipoxins
- This explains aspirin's anti-inflammatory effects beyond COX inhibition
Resolvin Biosynthesis:
- EPA + 15-LOX β 18-HPEPE β converted by 5-LOX β Resolvin E-series (RvE1, RvE2, RvE3)
- DHA + 15-LOX β 17-HpDHA β multiple pathways:
- β Resolvin D-series (RvD1-D6) via further 15-LOX action
- β Protectin D1 (also called Neuroprotectin D1 in neural tissue)
- β Maresin 1 and 2 via 12-LOX collaboration
Regulation of 15-LOX Expression:
- IL-4 and IL-13 (Th2 cytokines) β upregulate 15-LOX via STAT6 pathway
- IL-10 β upregulates 15-LOX during M2 macrophage polarization
- Increases 10-100 fold during resolution phase of inflammation
- Expression peaks 24-48 hours after inflammatory stimulus
- Positive feedback: SPMs β further 15-LOX expression via ALX-FPR2 signaling
- Glucocorticoids β enhance 15-LOX expression (synergy with endogenous resolution)
Substrate Competition:
- 15-LOX competes with COX-2 and 5-LOX for arachidonic acid
- Omega-6/omega-3 ratio determines product profile
- High omega-6 β more 15-HETE (weakly anti-inflammatory)
- High omega-3 β more resolvins, protectins, maresins (potently pro-resolving)
15-LOX function represents the enzymatic bottleneck of inflammatory resolution in cPNI practice. Patients with chronic inflammatory conditions often show deficient SPM production despite adequate omega-3 intake, pointing to 15-LOX dysfunction as a critical factor. This connects directly to Metamodel 2 (Chronic Low-Grade Inflammation) β if 15-LOX cannot convert substrate to resolution mediators, inflammation persists even when the initial trigger is removed.
Clinical Context:
- Chronic inflammatory diseases: Failed resolution due to 15-LOX deficiency has been documented in rheumatoid arthritis (synovial tissue shows low 15-LOX despite high inflammation), inflammatory bowel disease, asthma, and periodontitis
- Metabolic dysfunction: Adipose tissue from obese patients shows reduced 15-LOX expression, contributing to metaflammation and insulin resistance β the selfish immune system prioritizes pro-inflammatory over pro-resolving pathways
- Neuroinflammation: Brain 15-LOX activity declines with aging and in neurodegenerative diseases; Protectins (neuroprotectin D1) require 15-LOX and are deficient in Alzheimer's disease
- Cardiovascular disease: 15-LOX in arterial walls generates both protective lipoxins and potentially harmful oxidized lipids (context-dependent)
Evolutionary Mismatch:
- Hunter-gatherer omega-6:omega-3 ratio (~1:1 to 4:1) provided balanced 15-LOX substrate
- Modern Western diet (omega-6:omega-3 ratio 15:1 to 20:1) shifts 15-LOX toward less effective products
- Chronic psychological stress β glucocorticoid resistance β impaired IL-4/IL-13 signaling β reduced 15-LOX induction
- This represents a double mismatch: substrate imbalance AND regulatory dysregulation
Biomarkers and Thresholds:
- Omega-3 index: <4% (high risk) vs >8% (optimal) for resolution capacity
- Lipoxin A4 serum levels: <100 pg/mL suggests deficient resolution; >200 pg/mL optimal
- RvE1 plasma: <5 pg/mL in inflammatory diseases vs 15-30 pg/mL in healthy resolution
- 15-HETE/LTB4 ratio: Should be >1.0 for balanced resolution; <0.5 indicates pro-inflammatory dominance
Intervention Implications:
- Substrate provision: EPA/DHA supplementation (2-4 g/day combined) provides 15-LOX substrate
- Enzyme upregulation: Low-dose aspirin (75-100 mg) acetylates COX-2 β ATL production (synergizes with omega-3)
- Cofactor support: Vitamin D enhances 15-LOX expression; deficiency (<30 ng/mL) impairs SPM synthesis
- Th2 cytokine support: Probiotics (especially Lactobacillus strains) β IL-10 production β 15-LOX upregulation
- Stress management: Chronic stress β cortisol resistance β blunted IL-4 response β reduced 15-LOX; mind-body interventions restore IL-4 sensitivity
- Timing matters: Omega-3 loading during acute inflammation (first 48 hours) optimizes 15-LOX substrate availability during resolution phase
Selfish Systems Perspective:
The selfish brain prioritizes neuroprotection over peripheral resolution, potentially sequestering DHA for neural tissue at the expense of systemic SPM production. The selfish immune system may downregulate 15-LOX during chronic threat perception (low-grade inflammation as defense against perceived pathogens), creating a resolution deficit. Addressing the perceived threat β gut dysbiosis, chronic infections, psychological stress β is necessary for 15-LOX restoration.
Clinical Pearl: A patient with adequate omega-3 intake (high RBC omega-3 index) but persistently low SPM levels likely has 15-LOX dysfunction, not substrate deficiency. Investigate: chronic stress, vitamin D status, Th1/Th2 imbalance, or genetic polymorphisms affecting 15-LOX activity.
- Two human isoforms: 15-LOX-1 (ALOX15, chromosome 17) is the major SPM-synthesizing enzyme; 15-LOX-2 (ALOX15B, chromosome 17) has different tissue distribution and substrate preference
- Iron-dependent catalysis: Requires non-heme FeΒ²βΊ/FeΒ³βΊ cycle; iron deficiency impairs 15-LOX activity and resolution
- Expression timing: Upregulated 10-100 fold during resolution phase (24-72 hours post-injury/infection), marking the "resolution switch"
- Substrate specificity: Km for arachidonic acid ~5-10 ΞΌM; 3-5 fold higher affinity for EPA and DHA in 15-LOX-1
- Product profiles: From AA β 15-HETE (weakly active); from EPA β 18-HEPE (resolvin precursor); from DHA β 17-HpDHA (multiple SPM precursor)
- Aspirin synergy: 75-100 mg aspirin β acetylated COX-2 β 15-epi-lipoxins that are 2-3 times more resistant to degradation than native lipoxins
- Transcellular requirement: Lipoxin synthesis requires 5-LOX (neutrophils) + 15-LOX (epithelial/platelets) cooperation β spatial organization matters
- Regulation cascade: IL-4/IL-13 β STAT6 β 15-LOX transcription; IL-10 β p38 MAPK β 15-LOX stabilization
- Peak activity pH: Optimal at pH 7.4; acidosis (pH <7.2) reduces activity by 40-60%, explaining poor resolution in acidotic tissues
- Polymorphisms: ALOX15 promoter variants (-5229G>A) associated with reduced expression and increased cardiovascular risk in some populations
- Omega-3 dependency: Resolvin/protectin/maresin synthesis is absolutely dependent on EPA/DHA availability; no alternative substrate exists
- Clinical timeline: 15-LOX upregulation begins ~6-12 hours post-inflammatory stimulus, peaks 24-48 hours, returns to baseline by 72-96 hours in successful resolution
- 5-LOX β cooperates in transcellular lipoxin biosynthesis; competitive relationship for arachidonic acid substrate; 5-LOX/15-LOX ratio determines pro-inflammatory vs pro-resolving balance
- 12-LOX β collaborates in maresin synthesis from DHA; tissue-specific expression patterns complement 15-LOX
- COX-2 β substrate competitor; aspirin-acetylated COX-2 becomes 15-LOX collaborator producing aspirin-triggered lipoxins
- Specialized pro-resolving mediators (SPMs) β 15-LOX is the master biosynthetic enzyme for this entire mediator class
- Lipoxins β first SPM class discovered; synthesized via 15-LOX/5-LOX transcellular cooperation or aspirin-modified pathway
- Resolvins β E-series from EPA and D-series from DHA, both requiring 15-LOX as initiating enzyme
- Protectins β DHA-derived SPMs requiring 15-LOX; neuroprotectin D1 is critical for brain resolution
- Maresins β macrophage-derived mediators synthesized via 12-LOX/15-LOX collaboration from DHA
- ALX-FPR2 receptor β G-protein coupled receptor activated by 15-LOX products (lipoxins, resolvins); mediates anti-inflammatory and pro-resolving effects
- Resolution of inflammation β 15-LOX activity is the enzymatic prerequisite for active resolution; deficiency causes failed resolution
- Arachidonic acid β primary omega-6 substrate; converted to 15-HETE and lipoxin precursors
- EPA β omega-3 substrate; 15-LOX initiates E-series resolvin synthesis
- DHA β omega-3 substrate; 15-LOX generates multiple SPM families (resolvins, protectins, maresins)
- Omega-3 β essential substrate provider; tissue levels directly correlate with 15-LOX product formation
- IL-4 β Th2 cytokine that upregulates 15-LOX via STAT6 pathway; links adaptive immunity to resolution capacity
- IL-10 β anti-inflammatory cytokine that stabilizes 15-LOX mRNA and enhances expression during M2 macrophage polarization
- M2 macrophages β express high levels of 15-LOX during resolution phase; source of resolvins and maresins
- Aspirin β acetylates COX-2 to redirect activity toward 15R-HETE production; synergizes with 15-LOX for ATL synthesis
- Chronic inflammation β often characterized by 15-LOX deficiency despite adequate substrate; enzymatic bottleneck in resolution
- Metaflammation β adipose tissue inflammation involves reduced 15-LOX expression; contributes to metabolic syndrome
- Neuroinflammation β brain 15-LOX deficiency impairs neuroprotectin synthesis; implicated in neurodegenerative diseases
- Insulin resistance β 15-LOX products (especially RvD1) enhance insulin sensitivity; deficiency contributes to metabolic dysfunction
- Vitamin D β upregulates 15-LOX expression; deficiency impairs SPM biosynthesis independent of substrate availability
- Iron β essential cofactor for 15-LOX catalytic activity; iron deficiency causes functional enzyme deficiency
- Neutrophils β provide LTA4 substrate for transcellular lipoxin synthesis; 5-LOX activity partners with epithelial 15-LOX
- Eosinophils β high 15-LOX-1 expression; source of lipoxins in allergic inflammation
- Efferocytosis β enhanced by 15-LOX products (resolvins, maresins); impaired when 15-LOX is deficient